Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy.

Chou CK, Turtle CJ.

Bone Marrow Transplant. 2019 Aug;54(Suppl 2):780-784. doi: 10.1038/s41409-019-0602-5. Review.

PMID:
31431714
2.

Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells.

Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu V, Voutsinas J, Sorror M, Turtle CJ, Maloney DG, Bar M.

Biol Blood Marrow Transplant. 2019 Aug 13. pii: S1083-8791(19)30517-8. doi: 10.1016/j.bbmt.2019.08.003. [Epub ahead of print]

PMID:
31419568
3.

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

Chow VA, Gopal AK, Maloney DG, Turtle CJ, Smith SD, Ujjani CS, Shadman M, Cassaday RD, Till BG, Tseng YD, Warren EH, Shustov AR, Menon MP, Bhark S, Acharya UH, Mullane E, Hannan LM, Voutsinas JM, Gooley TA, Lynch RC.

Am J Hematol. 2019 Aug;94(8):E209-E213. doi: 10.1002/ajh.25505. Epub 2019 May 21. No abstract available.

PMID:
31056762
4.

Reply.

Lee DW, Mead E, Santomasso BD, Turtle CJ, Grupp SA, Neelapu SS.

Biol Blood Marrow Transplant. 2019 Jun;25(6):e211-e212. doi: 10.1016/j.bbmt.2019.03.019. Epub 2019 Mar 23. No abstract available.

PMID:
30910604
5.

Toxicities of CD19 CAR-T cell immunotherapy.

Hirayama AV, Turtle CJ.

Am J Hematol. 2019 May;94(S1):S42-S49. doi: 10.1002/ajh.25445. Epub 2019 Mar 6. Review.

PMID:
30784102
6.

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.

Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, Li D, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Acharya UH, Cassaday RD, Chapuis AG, Dhawale TM, Hendrie PC, Kiem HP, Lynch RC, Ramos J, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ.

Blood. 2019 Apr 25;133(17):1876-1887. doi: 10.1182/blood-2018-11-887067. Epub 2019 Feb 19.

PMID:
30782611
7.

Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies.

Tuazon SA, Li A, Gooley T, Eunson TW, Maloney DG, Turtle CJ, Linenberger ML, Connelly-Smith LS.

Transfusion. 2019 May;59(5):1773-1780. doi: 10.1111/trf.15178. Epub 2019 Feb 6.

PMID:
30729531
8.

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.

Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, Gooley TA, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Schoch G, Chapuis AG, Till BG, Kiem HP, Ramos JD, Shadman M, Cassaday RD, Acharya UH, Riddell SR, Maloney DG, Turtle CJ.

Blood. 2019 Apr 11;133(15):1652-1663. doi: 10.1182/blood-2018-11-883710. Epub 2019 Feb 6.

PMID:
30728140
9.

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS.

Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25. Review.

10.

Cytomegalovirus Exposure in the Elderly Does Not Reduce CD8 T Cell Repertoire Diversity.

Lindau P, Mukherjee R, Gutschow MV, Vignali M, Warren EH, Riddell SR, Makar KW, Turtle CJ, Robins HS.

J Immunol. 2019 Jan 15;202(2):476-483. doi: 10.4049/jimmunol.1800217. Epub 2018 Dec 12.

11.

Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies.

Gust J, Taraseviciute A, Turtle CJ.

CNS Drugs. 2018 Dec;32(12):1091-1101. doi: 10.1007/s40263-018-0582-9.

PMID:
30387077
12.

Not so crystal clear: observations from a case of crystalline arthritis with cytokine release syndrome (CRS) after chimeric antigen receptor (CAR)-T cell therapy.

Chung SH, Hughes G, Koffman B, Turtle CJ, Maloney DG, Acharya UH.

Bone Marrow Transplant. 2019 Apr;54(4):632-634. doi: 10.1038/s41409-018-0357-4. Epub 2018 Oct 5. No abstract available.

PMID:
30291306
13.

Driving CARs Across New Borders.

Turtle CJ, Adair JE.

Hum Gene Ther. 2018 May;29(5):529. doi: 10.1089/hum.2018.29065.cjt. No abstract available.

PMID:
29715075
14.

Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.

Gauthier J, Turtle CJ.

Curr Res Transl Med. 2018 May;66(2):50-52. doi: 10.1016/j.retram.2018.03.003. Epub 2018 Apr 3. Review.

15.

Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.

Taraseviciute A, Tkachev V, Ponce R, Turtle CJ, Snyder JM, Liggitt HD, Myerson D, Gonzalez-Cuyar L, Baldessari A, English C, Yu A, Zheng H, Furlan SN, Hunt DJ, Hoglund V, Finney O, Brakke H, Blazar BR, Berger C, Riddell SR, Gardner R, Kean LS, Jensen MC.

Cancer Discov. 2018 Jun;8(6):750-763. doi: 10.1158/2159-8290.CD-17-1368. Epub 2018 Mar 21.

16.

CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era.

Hay KA, Turtle CJ.

Immunotherapy. 2018 Feb 1;10(4):251-254. doi: 10.2217/imt-2017-0162. No abstract available.

PMID:
29421980
17.

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.

Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, Riddell SR, Maloney DG, Boeckh M, Turtle CJ.

Blood. 2018 Jan 4;131(1):121-130. doi: 10.1182/blood-2017-07-793760. Epub 2017 Oct 16.

18.

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, Chen J, Chung D, Harju-Baker S, Özpolat T, Fink KR, Riddell SR, Maloney DG, Turtle CJ.

Cancer Discov. 2017 Dec;7(12):1404-1419. doi: 10.1158/2159-8290.CD-17-0698. Epub 2017 Oct 12.

19.

Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation.

Bhattacharyya A, Hanafi LA, Sheih A, Golob JL, Srinivasan S, Boeckh MJ, Pergam SA, Mahmood S, Baker KK, Gooley TA, Milano F, Fredricks DN, Riddell SR, Turtle CJ.

Biol Blood Marrow Transplant. 2018 Feb;24(2):242-251. doi: 10.1016/j.bbmt.2017.10.003. Epub 2017 Oct 9.

20.

Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.

Cornetta K, Duffy L, Turtle CJ, Jensen M, Forman S, Binder-Scholl G, Fry T, Chew A, Maloney DG, June CH.

Mol Ther. 2018 Jan 3;26(1):280-288. doi: 10.1016/j.ymthe.2017.09.008. Epub 2017 Sep 12.

21.

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, López JA, Chen J, Chung D, Harju-Baker S, Cherian S, Chen X, Riddell SR, Maloney DG, Turtle CJ.

Blood. 2017 Nov 23;130(21):2295-2306. doi: 10.1182/blood-2017-06-793141. Epub 2017 Sep 18.

22.

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, Riddell SR, Maloney DG.

J Clin Oncol. 2017 Sep 10;35(26):3010-3020. doi: 10.1200/JCO.2017.72.8519. Epub 2017 Jul 17.

23.

Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies.

Hay KA, Turtle CJ.

Drugs. 2017 Mar;77(3):237-245. doi: 10.1007/s40265-017-0690-8. Review.

24.

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.

Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, Soma L, Wood B, Li D, Heimfeld S, Riddell SR, Maloney DG.

Sci Transl Med. 2016 Sep 7;8(355):355ra116. doi: 10.1126/scitranslmed.aaf8621.

25.

CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses.

Fromm PD, Papadimitrious MS, Hsu JL, Van Kooten Losio N, Verma ND, Lo TH, Silveira PA, Bryant CE, Turtle CJ, Prue RL, Vukovic P, Munster DJ, Nagasaki T, Barnard RT, Mahler SM, Anguille SA, Berneman Z, Horvath LG, Bradstock KF, Joshua DE, Clark GJ, Hart DN.

Oncoimmunology. 2016 May 5;5(6):e1168555. doi: 10.1080/2162402X.2016.1168555. eCollection 2016 Jun.

26.

Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape.

Turtle CJ, Maloney DG.

Expert Rev Hematol. 2016 Aug;9(8):719-21. doi: 10.1080/17474086.2016.1203251. Epub 2016 Jul 4. No abstract available.

PMID:
27322438
27.

CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies.

Turtle CJ, Riddell SR, Maloney DG.

Clin Pharmacol Ther. 2016 Sep;100(3):252-8. doi: 10.1002/cpt.392. Epub 2016 Jun 17.

PMID:
27170467
28.

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG.

J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25.

29.

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.

Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, Smithers H, Jensen MC, Riddell SR, Maloney DG, Turtle CJ.

Blood. 2016 May 19;127(20):2406-10. doi: 10.1182/blood-2015-08-665547. Epub 2016 Feb 23.

30.

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.

Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, Riddell SR.

Leukemia. 2016 Feb;30(2):492-500. doi: 10.1038/leu.2015.247. Epub 2015 Sep 15.

31.

Susceptibility of commonly used ferritin assays to the classic hook effect.

Ranjitkar P, Turtle CJ, Harris NS, Holmes DT, Pyle-Eilola A, Maloney DG, Greene DN.

Clin Chem Lab Med. 2016 Feb;54(2):e41-3. doi: 10.1515/cclm-2015-0604. No abstract available.

PMID:
26351953
32.

Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.

Riddell SR, Sommermeyer D, Berger C, Liu LS, Balakrishnan A, Salter A, Hudecek M, Maloney DG, Turtle CJ.

Cancer J. 2014 Mar-Apr;20(2):141-4. doi: 10.1097/PPO.0000000000000036. Review.

33.

Chimeric antigen receptor modified T cell therapy for B cell malignancies.

Turtle CJ.

Int J Hematol. 2014 Feb;99(2):132-40. doi: 10.1007/s12185-013-1490-x. Epub 2013 Dec 14. Review.

PMID:
24338745
34.

HLA engineering of human pluripotent stem cells.

Riolobos L, Hirata RK, Turtle CJ, Wang PR, Gornalusse GG, Zavajlevski M, Riddell SR, Russell DW.

Mol Ther. 2013 Jun;21(6):1232-41. doi: 10.1038/mt.2013.59. Epub 2013 Apr 30.

35.

Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo.

McGoldrick SM, Bleakley ME, Guerrero A, Turtle CJ, Yamamoto TN, Pereira SE, Delaney CS, Riddell SR.

Blood. 2013 Apr 4;121(14):2796-803. doi: 10.1182/blood-2012-09-453720. Epub 2013 Feb 14.

36.
37.

Engineered T cells for anti-cancer therapy.

Turtle CJ, Hudecek M, Jensen MC, Riddell SR.

Curr Opin Immunol. 2012 Oct;24(5):633-9. doi: 10.1016/j.coi.2012.06.004. Epub 2012 Jul 18. Review.

38.

Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.

Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR.

Blood. 2012 Jan 5;119(1):72-82. doi: 10.1182/blood-2011-07-366419. Epub 2011 Oct 26.

39.

Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161(hi) CD8α⁺ semi-invariant T cells.

Turtle CJ, Delrow J, Joslyn RC, Swanson HM, Basom R, Tabellini L, Delaney C, Heimfeld S, Hansen JA, Riddell SR.

Blood. 2011 Sep 8;118(10):2752-62. doi: 10.1182/blood-2011-02-334698. Epub 2011 Jul 25.

40.

HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo.

Chapuis AG, Casper C, Kuntz S, Zhu J, Tjernlund A, Diem K, Turtle CJ, Cigal ML, Velez R, Riddell S, Corey L, Greenberg PD.

Blood. 2011 May 19;117(20):5391-402. doi: 10.1182/blood-2010-11-320226. Epub 2011 Mar 21.

41.

Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy.

Turtle CJ, Riddell SR.

Curr Opin Immunol. 2011 Apr;23(2):299-305. doi: 10.1016/j.coi.2010.12.012. Epub 2011 Jan 14. Review.

42.

Overlap and effective size of the human CD8+ T cell receptor repertoire.

Robins HS, Srivastava SK, Campregher PV, Turtle CJ, Andriesen J, Riddell SR, Carlson CS, Warren EH.

Sci Transl Med. 2010 Sep 1;2(47):47ra64. doi: 10.1126/scitranslmed.3001442.

43.

The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR.

Blood. 2010 Nov 25;116(22):4532-41. doi: 10.1182/blood-2010-05-283309. Epub 2010 Aug 11.

44.

Artificial antigen-presenting cells for use in adoptive immunotherapy.

Turtle CJ, Riddell SR.

Cancer J. 2010 Jul-Aug;16(4):374-81. doi: 10.1097/PPO.0b013e3181eb33a6. Review.

45.

A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy.

Turtle CJ, Swanson HM, Fujii N, Estey EH, Riddell SR.

Immunity. 2009 Nov 20;31(5):834-44. doi: 10.1016/j.immuni.2009.09.015. Epub 2009 Oct 29.

46.

Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit.

Gutman JA, Turtle CJ, Manley TJ, Heimfeld S, Bernstein ID, Riddell SR, Delaney C.

Blood. 2010 Jan 28;115(4):757-65. doi: 10.1182/blood-2009-07-228999. Epub 2009 Oct 12.

47.

Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells.

Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, Riddell SR, Warren EH, Carlson CS.

Blood. 2009 Nov 5;114(19):4099-107. doi: 10.1182/blood-2009-04-217604. Epub 2009 Aug 25.

48.

Adoptive transfer of virus-specific and tumor-specific T cell immunity.

Berger C, Turtle CJ, Jensen MC, Riddell SR.

Curr Opin Immunol. 2009 Apr;21(2):224-32. doi: 10.1016/j.coi.2009.02.010. Epub 2009 Mar 21. Review.

49.

Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus.

Dai Z, Turtle CJ, Booth GC, Riddell SR, Gooley TA, Stevens AM, Spies T, Groh V.

J Exp Med. 2009 Apr 13;206(4):793-805. doi: 10.1084/jem.20081648. Epub 2009 Mar 16.

50.

Clinical-scale elutriation as a means of enriching antigen-presenting cells and manipulating alloreactivity.

Micklethwaite KP, Garvin FM, Kariotis MR, Yee LL, Hansen AM, Antonenas V, Sartor MM, Turtle CJ, Gottlieb DJ.

Cytotherapy. 2009;11(2):218-28. doi: 10.1080/14653240802702160.

PMID:
19242837

Supplemental Content

Loading ...
Support Center